The U.S. Federal Trade Commission said on Friday that it had approved generic drugmaker Mylan NV’s planned purchase of Pfizer’s Upjohn, subject to conditions. The proposed transaction was announced in July...
China’s Fosun-owned Gland Pharma gets Sebi nod for proposed ₹6,000 cr IPO
Gland Pharma Ltd, which is majority-owned by China’s Fosun group, has received the Securities and Exchange Board of India’s (Sebi) approval to go ahead with its proposed ₹6,000 crore IPO, a person aware of the...
Piramal Pharma completes 20% stake sale to Carlyle
Piramal Enterprises-arm Piramal Pharma has completed sale of 20 per cent stake in the company for Rs 3,523.40 crore to US-based global investment firm Carlyle Group Inc. Piramal Pharma has received Rs 3,523.40 crore...
Pfizer to buy 9.9% of CStone for $200 million, eyes collaboration
CStone Pharmaceuticals said on Wednesday a unit of Pfizer Inc had agreed to buy a 9.9% stake for HK$1.55 billion ($200 million), as the Hong Kong-listed biopharmaceutical firm seeks to improve the commercialisation of...
Gilead to buy cancer drugmaker Immunomedics for $21 billion
Gilead Sciences Inc will acquire biopharmaceutical company Immunomedics Inc for $21 billion, a move that will strengthen its cancer portfolio by gaining access to a promising drug, the two companies said in a joint...
Baring India Private Equity Fund III sells 7.36% in Shilpa Medicare for ₹306 crore
Private equity investor Baring India Fund III sold a 7.36% stake in Shilpa Medicare worth ₹306 crore, on Friday, through an open market transaction. As per the bulk deal data on the exchange, 6 million shares or 7.36%...
Takeda to sell Japan consumer health unit valued at $2.3 billion to Blackstone
Takeda Pharmaceutical Co said on Monday it would sell its Japanese consumer healthcare business to US buyout fund Blackstone Group, as it aims to focus on developing drugs for unmet medical needs and rare diseases...
Kohlberg & Co, Mubadala take controlling stake in PCI Pharma
Private equity firm Kohlberg & Company and Abu Dhabi state investor Mubadala have agreed to take a controlling stake in PCI Pharma Services, a U.S. pharmaceutical outsourcing company, from Partners Group, the...
Johnson & Johnson borrowing $7.5 billion for Momenta in latest M&A bond sale
Johnson & Johnson is tapping the bond market for $7.5 billion to help fund its acquisition of Momenta Pharmaceuticals Inc., adding to a week that’s seen a resurgence in financing for takeovers. The drugmaker is the...
Johnson & Johnson’s $6.5-bn pact to buy Momenta is year’s biggest pharma deal
Johnson & Johnson agreed to pay $6.5 billion in cash to acquire Momenta Pharmaceuticals Inc., a maker of autoimmune-disease drugs, in the largest pharmaceutical-industry merger this year. Though the price tag falls...
Takeda preparing to sell Japan consumer health unit to Blackstone – Kyodo
Japan’s Takeda Pharmaceutical Co Ltd is making final arrangements to sell its domestic over-the-counter (OTC) business to U.S. investment fund Blackstone Group Inc, Kyodo News reported on Wednesday. Takeda, Japan’s...
Biological E acquires Akorn India to ramp up vaccine & injectable medicine capacities
Hyderabad based vaccine manufacturer Biological E, which is currently conducting clinical trials on a Covid-19 vaccine candidate, has announced acquiring Akorn India with injectables and specialty sterile...
